Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Medicure Inc. stock logo
MPH
Medicure
C$2.98
C$2.18
C$0.85
▼
C$2.99
C$31.10M0.9769463,582 shs1,502 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Medicure Inc. stock logo
MPH
Medicure
0.00%+2.05%+19.20%+186.54%+195.05%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Medicure Inc. stock logo
MPH
Medicure
C$2.98
C$2.18
C$0.85
▼
C$2.99
C$31.10M0.9769463,582 shs1,502 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Medicure Inc. stock logo
MPH
Medicure
0.00%+2.05%+19.20%+186.54%+195.05%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Medicure Inc. stock logo
MPH
Medicure
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Medicure Inc. stock logo
MPH
Medicure
C$32.08M0.97C$1.20 per share2.49C$1.11 per share2.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Medicure Inc. stock logo
MPH
Medicure
-C$2.03M-C$0.72N/AN/AN/A-23.23%-54.73%-5.63%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Medicure Inc. stock logo
MPH
Medicure
N/A2.24%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Medicure Inc. stock logo
MPH
Medicure
6.02
0.97
1.29

Institutional Ownership

CompanyInstitutional Ownership
Medicure Inc. stock logo
MPH
Medicure
4.85%

Insider Ownership

CompanyInsider Ownership
Medicure Inc. stock logo
MPH
Medicure
26.68%
CompanyEmployeesShares OutstandingFree FloatOptionable
Medicure Inc. stock logo
MPH
Medicure
N/A10.44 millionN/ANot Optionable

Recent News About These Companies

Medicure Grants Stock Options to Key Personnel
Medicure Stock Price History
Medicure Inc. (MPH:CA) Q3 2025 Earnings Call Transcript
Hydro One, Loblaw, Medicure at 52-Week Highs on News
Medicure Inc. to Announce Q3 2025 Financial Results
Medicure to Present Financial Results on August 21…
Medicure Inc. to Announce Q2 2025 Financial Results
Medicure stock logo

Medicure CVE:MPH

C$2.98 0.00 (0.00%)
As of 10/9/2026 03:59 PM Eastern

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.